Valion Bio’s Interim CEO Scores 50,000 RSUs at Zero Cost, Signalling a Bold Turnaround Play in Volatile Biotech Stock.
Valion Bio’s CEO secures 50,000 RSUs after a 1‑for‑25 reverse split—signaling confidence and a strategic shift toward its flagship candidate Entolimod.
3 minutes to read